Search Results - "Palangié, T"

Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer by Pierga, J.-Y, Mouret, E, Laurence, V, Diéras, V, Savigioni, A, Beuzeboc, P, Dorval, T, Palangié, T, Jouve, M, Pouillart, P

Get full text

Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer: the role of clinical response by Pierga, J.-Y, Mouret, E, Laurence, V, Diéras, V, Savigioni, A, Beuzeboc, P, Dorval, T, Palangié, T, Jouve, M, Pouillart, P

“…The aim of this retrospective study was to assess predictive factors for clinical response to preoperative chemotherapy and prognostic factors for survival…”
Get full text

Dose-intense salvage therapy after neoadjuvant chemotherapy: feasibility and preliminary results by PALANGIE, T, PIERGA, J. Y, POUILLART, P

“…Breast cancer patients who, following treatment with primary chemotherapy (FAC 50) present an axillary node involvement of more than 4 nodes together with…”
Get full text

Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer by PIERGA, J-Y, MOURET, E, EXTRA, J-M, ASSELAIN, B, POUILLART, P, DIERAS, V, LAURENCE, V, BEUZEBOC, P, DORVAL, T, PALANGIE, T, JOUVE, M, VINCENT-SALOMON, A, SCHOLL, S

“…Neoadjuvant chemotherapy is able to reduce the size of the majority of breast tumours and down-stage axillary-node status. The aim of this study was to assess…”
Get full text

Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6 by Scholl, S M, Fourquet, A, Asselain, B, Pierga, J Y, Vilcoq, J R, Durand, J C, Dorval, T, Palangié, T, Jouve, M, Beuzeboc, P

“…The aim of this study was to assess a potential advantage in survival by neoadjuvant as compared to adjuvant chemotherapy. 414 premenopausal patients with…”
Get more information

Breast tumour response to primary chemotherapy predicts local and distant control as well as survival by Scholl, S.M., Pierga, J.Y., Asselain, B., Beuzeboc, P., Dorval, T., Garcia-Giralt, E., Jouve, M., Palangié, T., Remvikos, Y., Durand, J.C., Fourquet, A., Pouillart, P.

“…The purpose of the present paper was to evaluate correlations between clinical response to chemotherapy and outcome in a subgroup analysis of premenopausal…”
Get full text

First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer : toxicity and response (PEGASE 02 trial) by VIENS, P, PALANGIE, T, COSTA, B, DELVA, R, CURE, H, ROUSSEAU, F, GUILOT, A, MOUSSEAU, M, FERRERO, J. M, BARDOU, V. J, JACQUEMIER, J, POUILLART, P, JANVIER, M, FABBRO, M, ROCHE, H, DELOZIER, T, LABAT, J. P, LINASSIER, C, AUDHUY, B, FEUILHADE, F

“…Despite the generalization of induction chemotherapy and a better outcome for chemosensitive diseases, the prognosis of inflammatory breast cancer (IBC) is…”
Get full text

Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients by Pierga, J. Y., Robain, M., Jouve, M., Asselain, B., Diéras, V., Beuzeboc, P., Palangié, T., Dorval, T., Extra, J.-M., Scholl, S., Pouillart, P.

“…Background: In cancer patients, correlation between response to chemotherapy and gain in survival remains debated. We addressed this question in a multivariate…”
Get full text

Overexpression of PDGF receptor β in dermal fibroblasts of lymphangitic post radiotherapy relapses of breast carcinoma by Pierga, J-Y., Benyahia, B., Cammilleri, S., Palangié, T., Beuzeboc, P., Pouillart, P., Magdelénat, H.

“…Lymphangitic relapses of breast cancer, initiating in the area irradiated for conservative treatment, are rare but not uncommon. Clinical and…”
Get full text

BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic by STOPPA-LYONNET, D, LAURENT-PUIG, P, BONAÏTI-PELLIE, C, THOMAS, G, ESSIOUX, L, PAGES, S, ITHIER, G, LIGOT, L, FOURQUET, A, SALMON, R. J, CLOUGH, K. B, POUILLART, P

Get full text

Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first‐line doxorubicin‐containing chemotherapy by Pierga, Jean‐Yves, Asselain, Bernard, Jouve, Michel, Diéras, Véronique, Carton, Mathieu, Laurence, Valérie, Girre, Véronique, Beuzeboc, Philippe, Palangié, Thao, Dorval, Thierry, Pouillart, Pierre

“…BACKGROUND The objective of the current study was to analyze the impact of adjuvant chemotherapy in comparison with other prognostic parameters on the outcome…”
Get full text

High-Dose Sequential Chemotherapy With Recombinant Granulocyte Colony-Stimulating Factor and Repeated Stem-Cell Support for Inflammatory Breast Cancer Patients: Does Impact on Quality of Life Jeopardize Feasibility and Acceptability of Treatment? by MACQUART-MOULIN, G, VIENS, P, PALANGIE, T, BOUSCARY, M.-L, DELOZIER, T, ROCHE, H, JANVIER, M, FABBRO, M, MOATTI, J.-P

“…This study was designed to investigate the quality of life (QOL) of patients enrolled onto the High-Dose Chemotherapy for Breast Cancer Study Group trial…”
Get full text

Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer by Robain, M., Pierga, J.Y., Jouve, M., Asselain, B., Diéras, V., Beuzeboc, P., Palangié, T., Dorval, T., Extra, J.-M., Scholl, S., Pouillart, P.

“…Since response to chemotherapy is a major determinant of survival in metastatic breast cancer, the purpose of our study was to analyse the predictive factors…”
Get full text

ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy by Vincent-Salomon, A., Carton, M., Freneaux, P., Palangie, T., Beuzeboc, P., Mouret, E., de Crémoux, P., Coué, O., Zafrani, B., Nicolas, A., Clough, K., Fourquet, A., Pouillart, P., Sastre-Garau, X.

“…The predictive value of ERBB2 amplification/expression to doxorubicin use is controversial. Preoperative chemotherapy, followed by the pathological assessment…”
Get full text

Prognostic factors in inflammatory breast cancer and therapeutic implications by Palangie, T, Mosseri, V, Mihura, J, Campana, F, Beuzeboc, P, Dorval, T, Garcia-Giralt, E, Jouve, M, Scholl, S, Asselain, B

“…223 inflammatory breast cancer patients were diagnosed at the Institut Curie between 1977 and 1987. Patients received chemotherapy and radiation treatment…”
Get more information

Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer by SCHOLL, S. M, BASCOU, C. H, MOSSERI, V, OLIVARES, R, MAGDELENAT, H, DORVAL, T, PALANGIE, T, VALIDIRE, P, POUILLART, P, STANLEY, E. R

“…Serum samples from 82 patients with epithelial ovarian cancer, previously assayed for CA125, were assayed for circulating colony-stimulating factor 1 (CSF-1)…”
Get full text

Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer by Dorval, T, Soussain, C, Beuzeboc, P, Garcia-Giralt, E, Jouve, M, Livartowski, A, Mosseri, V, Palangié, T, Scholl, S, Sastre, X, Pouillart, P

“…The prognosis of advanced ovarian cancer is very poor, with about 15% of patients surviving at five years. Since most of these patients will relapse and/or…”
Get more information

Post-Operative 5FU-Docetaxel after High-Dose of Pre-Operative Epirubicin-Cyclophosphamide for Treatment of Inflammatory Breast Cancer: Results of the FNCLCC-Pegase 07 Trial by Viens, P., Palangié, T., Ferrero, J., Chollet, P., Bachelot, T., Delva, R., Fabbro, M., Janvier, M., Lotz, J., Linassier, C., Dohollou, N., Eymard, J., Leduc, B., Genève, J., Martin, A., Boher, J., Roché, H.

“…Purpose: to evaluate the benefit of a post-operative Fluorouracil-Docetaxel (D-5FU) regimen after pre-operative Epirubicin-Cyclophosphamide (EC) and…”
Get full text

Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90) by PIERGA, J.-Y, JOUVE, M, POUILLART, P, ASSELAIN, B, LIVARTOWSKI, A, BEUZEBOC, P, DIERAS, V, SCHOLL, S, DORVAL, T, PALANGIE, T, GARCIA-GIRALT, E

“…Infusional 5-fluorouracil in advanced breast cancer has been associated with improved clinical response rates when compared with conventional bolus therapy. As…”
Get full text

Phase II Trial of Doxorubicin, 5-Fluorouracil, Etoposide, and Cisplatin in Advanced or Recurrent Endometrial Carcinoma by Pierga, J-Y., Diéras, V., Beuzeboc, P., Dorval, T., Palangié, T., Jouve, M., Scholl, S.M., Garcia-Giralt, E., Pouillart, P.

“…We have previously reported an overall response rate of 41% and a median survival duration of 14 months in a series of 49 patients with metastatic or recurrent…”
Get full text